We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Elcap - I agree enirely with you and BasilAlderman's comments yesterday. This isn't about ramping it's about basic comms/PR to keep investors properly informed.
Elcap, Completely agree with you, a simple road map would be very simple to publish and update.
On a separate topic I just acquired some more shares as feel the next move is upwards.
Lutonnews, good luck with the exit strategy, you deserve to be rewarded for your long term loyalty to this company, as we all do.. :+) GLA. Andy.
I understand Dr's Parker & Mitchell do look at this BB. The potential problem here is that a lot of LTH's are weary of all the delays and lack of info. Market sentiment is a big part of where the SP settles. If a company is serial ramper the market gets fed up with it. Also if a company doesn't tell the market anything either, and never delivers, the market perception can be equally negative. The trick is to find the happy medium, build sentiment, build the SP then finish the process off with DELIVERING. Sareum are going from Points A - D, but not taking the market with them on the journey. As far as we know we are still at point A, then all of a sudden we will jump to point D (hopefully). I would prefer to know what point on the journey we are. If we are at point B or point C, let us know.
Just a frustrated Friday rant.
It's been (and still is) a very busy week at work.
Elcap
Feel your pain luton, I really do, .. likewise.. 1-1.5 and I'm out for good. It's built a steely weariness in me if that's even a term.... I refuse to Av Down on this one anymore...
I hope so zylo .
I am probably one of SARs longest and most patient investors but will need to cash in my chips here before next March to help the last of my sons get on the property ladder .
Could use some of my savings but being invested in SAR for well over a decade is probably long enough.
A mere 3p per share would do me fine any more and one Rainbow Chaser will be extremely happy.
ATB.
my wild hunch and pure speculation is...
that a TO will be on the cards, and the party/ies are waiting on some key events to happen, could be more data from TYK2 etc...... it will all come out in the wash this year. the end game
could have just said
nor running the risk of unnecessary interference from the AiM team.... end of
its very telling...
nor running the risk of unnecessary interference from either the AiM team or the Takeover Panel - I am afraid that your suggestion of announcing either CDAs or closed periods might very well trigger either or both institution to seek clarification,
Thoth2
I found the comment “takeover panel” intriguing also.......food for thought!
great effort elcap, its a shame SAR have to inform their share holders in this way, very peculiar?
Oh, and can we stick with SAREUM please guys!
If he let it slip, it is intentional. I've read the reply a few times now. He's defo p i ssed off about being asked to pull some news out of thin air all the time. Hope he feels better now. He's got work to do. :-)
Subtle :) https://www.thetakeoverpanel.org.uk/ would be my preferred outcome after years here whether that be towards the end of preclinical or during a phase 1 the latter would probably be closer to some of the figures previously quote around here.
Aye- I missed that Parker has let slip that one.
Glad we have collectively shaken the Sareum tree a bit today. Well done everyone. Pretty bland riposte but at least he replied and perhaps the shareholder frustrations are filtering through. It was certainly a much more well crafted response than Tim’s last month. However, In my book actions speak louder than words or the occasional tweet. It really is time for Sareum to deliver after all these years. I will await the next RNS with renewed interest. Brighty
great response.
mentioning the "takeover panel" is a first. hmm hmm hmm. locked and loaded here. get buckled up gents.
Well done on the email elcap. Great you got a response.
So no update till year end, and no speculation from Parker straight to the point, I agree with him what we know is what we know from RNS, after all this is a site for people’s opinions unless directed to a statement in RNS, sleek business model uses the cash resources and time for better things unfortunately like getting the molecules ready for the end of preclinical year end, forget the covid nonsense only real updates here!
That's a fair response from Dr Parker- say to me that when news comes it will be fantastic as he will then have justification to speak up.
Wow, that is a very honest answer. I think everyone knows which side of the fence I sit. We need to let them get on with it. Forget Covid and get rich schemes. The real value if TYK2 and what it was developed for. Covid may be a bonus but we don't want it to derail the development cycle. Thank you for sending the email, Elcap and thank you, Tim for the honest reply.
Dear Mr...........,
Very many thanks for your email and I note your concerns. We will be making a trading statement, as we usually do following the year-end and we expect that this will be done via the new platform https://www.investormeetcompany.com/, which will allow a more interactive session with shareholders. We will be announcing the date of the Trading Statement in advance.
I understand your frustration with the news flow, however, you must recall that all of our programmes are, or have been, partnered at some stage as a means of making progress for remarkably little cost, in line with the amount which we have raised over the years from shareholders (which, in comparison with most of the companies quoted in the list below, is very small). The price that is paid, however, is that we lose control of the timeframe with which work is done - think of the delay in the publication of lupus data from the TYK2 programme since they are owned by the US Department of Defence and not by Sareum.
Most notably, do recall that Sareum is the minority partner with Cancer Research for the chk1 programme and not a party to the licensing contract with Sierra - unfortunately we are, therefore, a spectator in the current progress of the drug and we have always ensured that our shareholders are informed of any developments with the shortest possible delay; I have always interacted with both Sierra and CPF to remind them that, as a listed company, Sareum has responsibilities to its shareholders too.
I am a firm believer in open interaction with shareholders and happy to help with concerns as they arise. I am not, however, in the business of “ramping” the stock without justification, nor running the risk of unnecessary interference from either the AiM team or the Takeover Panel - I am afraid that your suggestion of announcing either CDAs or closed periods might very well trigger either or both institution to seek clarification, which would not be the best use of a small management team’s time.
I hope that this is helpful to you.
With best regards,
Dr Stephen Parker